Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced ...

The company will highlight 18 presentations covering ... Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab ...

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

May 05, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ... and cancer therapy Libtayo added $285.1M with ~19% and ~8% ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q'25 - - Reported positive ...

The company’s Chief Scientific Officer, George D. Yancopoulos, M.D., Ph.D., expressed optimism about the potential of these treatments, including Libtayo, which is already a standard of care for ...